ATLANTA, March 28, 2016 -- HD Supply Holdings, Inc. (Nasdaq:HDS) today announced that its indirect wholly-owned subsidiary, HD Supply, Inc. (“HD Supply”), intends to commence a private offering of $1,000,000,000 of Senior Notes due 2024 (the “Notes”). There can be no assurance that the proposed offering of Notes will be completed.
HD Supply intends to use the proceeds from the sale of the Notes, together with available cash, to refinance its outstanding $1,000,000,000 aggregate principal amount of 11.50% Senior Notes due 2020 and to pay related fees and expenses.
The Notes will be offered in a private offering exempt from the registration requirements of the United States Securities Act of 1933, as amended (the “Securities Act”). The Notes will be offered only to qualified institutional buyers pursuant to Rule 144A and to certain persons outside the United States pursuant to Regulation S, each under the Securities Act.
The Notes will not be and have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.
This press release is for informational purposes only and is not an offer to sell or purchase nor the solicitation of an offer to sell or purchase securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which, or to any person to whom such an offer, solicitation or sale would be unlawful.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management's beliefs and assumptions and information currently available to management. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond our control. We caution you that the forward-looking information presented in this press release is not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “plan,” “seek,” “comfortable with,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe” or “continue” or the negative thereof or variations thereon or similar terminology. A number of important factors could cause actual events to differ materially from those contained in or implied by the forward-looking statements, including those factors discussed in our filings with the U.S. Securities & Exchange Commission (the “SEC”), including our annual report on Form 10-K for the fiscal year ended January 31, 2016, and those described from time to time in our other filings with the SEC, which can be found at the SEC’s website www.sec.gov. Any forward-looking information presented herein is made only as of the date of this press release, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.
Investor Contact: Charlotte McLaughlin HD Supply Investor Relations 770-852-9100 [email protected] Media Contact: Quiana Pinckney, APR HD Supply Public Relations 770-852-9057 [email protected]


JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Italy Fines Apple €98.6 Million Over App Store Dominance
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



